Table 2.
Use of LMT in the overall ASCVD and non-ASCVD cohorts and subgroups
| ASCVD cohort (n=91 497) |
Non-ASCVD cohort (n=92 086) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Recent ACS | Other CHD | Ischaemic stroke/TIA | PAD | Total ASCVD | T2DM with CKD | T2DM without CKD | T1DM with CKD | T1DM without CKD | CKD alone | Total non-ASCVD | |
| High-intensity statin, %* | 62.4 | 34.6 | 21.5 | 23.2 | 31.4 | 20.0 | 18.6 | 29.0 | 21.1 | 11.1 | 17.0 |
| Monotherapy, % | 93.3 | 91.8 | 93.2 | 92.3 | 92.2 | 91.1 | 93.5 | 92.6 | 90.2 | 93.3 | 93.0 |
| Plus ezetimibe, % | 1.0 | 4.8 | 2.9 | 3.4 | 4.1 | 3.2 | 2.4 | 4.1 | 5.1 | 2.7 | 2.8 |
| Plus other non-statin LMT, % | 5.8 | 3.4 | 3.9 | 4.3 | 3.7 | 5.7 | 4.0 | 3.2 | 4.7 | 4.0 | 4.3 |
| Medium-intensity statin, %* | 22.6 | 41.4 | 46.2 | 44.3 | 42.1 | 44.7 | 43.0 | 39.5 | 36.5 | 33.1 | 40.4 |
| Monotherapy, % | 98.6 | 97.9 | 98.7 | 98.6 | 98.2 | 97.9 | 98.4 | 96.3 | 97.7 | 98.9 | 98.4 |
| Plus ezetimibe, % | 0.6 | 1.2 | 0.7 | 0.6 | 1.0 | 0.6 | 0.6 | 1.7 | 1.4 | 0.5 | 0.6 |
| Plus other non-statin LMT, % | 0.9 | 0.9 | 0.5 | 0.8 | 0.8 | 1.5 | 1.0 | 2.0 | 1.0 | 0.7 | 1.0 |
| Low-intensity statin, %* | 2.1 | 5.9 | 5.5 | 5.1 | 5.6 | 6.4 | 4.9 | 4.9 | 4.4 | 4.8 | 5.0 |
| Monotherapy, % | 93.8 | 95.9 | 97.4 | 97.1 | 96.3 | 96.2 | 98.1 | 89.2 | 95.6 | 98.3 | 97.7 |
| Plus ezetimibe, % | 6.3 | 3.2 | 1.7 | 2.3 | 2.8 | 2.3 | 1.1 | 8.1 | 2.7 | 1.0 | 1.4 |
| Plus other non-statin LMT, % | 0.0 | 0.9 | 0.8 | 0.6 | 0.8 | 1.6 | 0.7 | 2.7 | 1.6 | 0.7 | 0.9 |
| Non-statins only, %* | 0.9 | 2.0 | 1.7 | 1.9 | 1.9 | 2.5 | 1.6 | 3.9 | 2.0 | 1.7 | 1.8 |
| Ezetimibe, % | 70.4 | 61.3 | 65.5 | 55.6 | 61.6 | 47.9 | 54.2 | 58.6 | 61.6 | 45.5 | 51.5 |
| Other non-statin LMT, % | 29.6 | 38.7 | 34.5 | 44.4 | 38.4 | 52.1 | 45.8 | 41.4 | 38.4 | 54.5 | 48.5 |
| Not currently treated by LMT, %* | 12.1 | 16.2 | 25.1 | 25.4 | 19.0 | 26.4 | 31.9 | 22.7 | 35.9 | 49.4 | 35.8 |
| Prev high-intensity statin, % | 20.7 | 16.4 | 8.6 | 9.3 | 13.2 | 7.7 | 6.1 | 18.2 | 9.1 | 3.3 | 5.5 |
| Prev medium-intensity statin, % | 22.8 | 40.9 | 37.9 | 33.0 | 38.4 | 33.2 | 27.5 | 30.6 | 29.9 | 17.7 | 24.7 |
| Prev low-intensity statin, % | 5.6 | 10.0 | 6.9 | 6.8 | 8.5 | 7.3 | 4.9 | 10.0 | 4.4 | 3.9 | 4.7 |
| Prev non-statin LMT, % | 4.8 | 7.2 | 4.8 | 3.6 | 5.9 | 6.1 | 3.5 | 5.3 | 3.8 | 2.4 | 3.4 |
| No prev LMT, % | 46.1 | 25.5 | 41.8 | 47.3 | 34.0 | 45.7 | 58.0 | 35.9 | 52.8 | 72.7 | 61.7 |
*Numbers in this row denote absolute percentages, and add up to 100% vertically. All other numbers are relative percentages of the absolute percentages. ASCVD subgroups represent hierarchical categorisation. Non-ASCVD categorisations have been simplified by consideration of the qualifiers QRISK2 ≥10% and age >40 years as implicit in the definitions of T2DM and T1DM, respectively, with and without CKD, and of the qualifiers without T2DM + QRISK2 ≥10% or T1DM + age >40 as implicit in the definition of CKD alone.
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CKD, chronic kidney disease; LMT, lipid-modifying therapy; PAD, peripheral arterial disease; Prev, previously on; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.